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Abstract 
 
Background & Aims: Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a 
unique episomal replicative intermediate responsible for persistent infection of hepatocytes. 
Technical constraints have hampered the direct study of cccDNA maintenance and clearance 
mechanisms in patients. The aim of this study was to develop a sensitive and specific assay 
quantifying cccDNA in biopsy samples from chronic hepatitis B patients during different 
natural history phases and in patients undergoing antiviral therapy. 
Methods : Intrahepatic cccDNA levels were quantified by a specific real-time PCR assay. 
Ninety eight liver biopsy samples from patients in the major phases of the natural history of 
chronic hepatitis B and 32 pairs of samples from patients receiving adefovir dipivoxil (ADV) 
therapy were assessed. 
Results : cccDNA was detected, at levels ranging over three orders of magnitude, in patients 
in different phases of the natural history of chronic hepatitis B. cccDNA levels were strongly 
correlated with levels of total intracellular HBV DNA and serum HBV DNA. Fourty eight 
weeks of ADV therapy resulted in a significant 0.8 log decrease in cccDNA copies/cell. 
Changes in cccDNA were correlated with a similar reduction in serum HBsAg titer, but not 
with a decrease in the number of HBV antigen-positive cells during ADV treatment. 
Conclusion : cccDNA persists throughout the natural history of chronic hepatitis B, even in 
patients with serological evidence of viral clearance. Long term ADV therapy significantly 
decreased cccDNA levels by a primarily non-cytolytic mechanism.  
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Introduction 
Chronic hepatitis B virus (HBV) infection remains a major health problem affecting 
approximately 400 million people worldwide
1
. Although HBV replication is only mildly 
cytopathic, cellular immune responses directed against the virus can produce substantial liver 
damage and result in chronic hepatitis, cirrhosis, and hepatocellular carcinoma
1
. Chronic 
hepatitis B (CH-B) encompasses a broad spectrum of disease and can be divided into several 
phases of natural history which are distinguishable by serological and virological markers 
2
. 
One goal of antiviral therapy is to accelerate patients with chronic active disease into later 
natural history phases wherein viral replication abates and the incidence of serious liver 
disease is significantly reduced.  
Chronic infection is believed to be maintained by a replicative form of HBV DNA termed 
cccDNA. During infection, HBV cccDNA accumulates in cell nuclei where it persists as a 
stable episome and acts as a template for the transcription of viral genes
3,4
. Viral transcripts 
are translated into capsid and polymerase proteins and subsequently encapsidated and retro-
transcribed into new partially double-stranded viral genomes. DNA-containing nucleocapsids 
can be enveloped and secreted from the cell as mature virus or cycled back to the nucleus to 
maintain the cccDNA pool
5
. Considering the long half-life of hepatocytes, the limiting factor 
in eliminating infection is thought to be the clearance of cccDNA reservoirs from infected 
cells 
6,7
. Two immune mechanisms have been proposed to mediate cccDNA clearance: 1) a 
cytolytic mechanism by which infected cells are eliminated and replaced by cells from an 
uninfected lineage
8,9
 and 2) a non-cytolytic, cytokine-induced “curing” of infected cells10,11. 
There is evidence from animal models supporting each mechanism, and while these 
mechanisms are not mutually exclusive, it is currently unclear how infection is resolved in 
patients. 
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Despite the crucial role of cccDNA during persistent infection and the importance of 
understanding clearance mechanisms, few data have been collected from patients
12,13
. Indeed, 
our current understanding of cccDNA has been obtained primarily through studies of the 
woodchuck and duck hepatitis B virus models
7,8,14,15
. Historical obstacles to the study of 
HBV cccDNA have been 1) the requirement for liver biopsies, which are difficult to collect, 
especially from patients in quiescent natural history phases, and 2) the lack of sensitive, 
specific, and quantitative methods for detection of cccDNA from biopsies. In this study, we 
report the development of a novel real-time PCR assay that allowed us to quantify levels of 
cccDNA in biopsies collected from CH-B patients. To gain insight on the persistence of 
cccDNA and clearance mechanisms, we studied patients in different phases of the natural 
history of CH-B and a group of patients participating in a placebo-controlled trial of the 
recently approved nucleotide analog adefovir dipivoxil (ADV)
16,17
. These studies have 
provided novel insight into cccDNA persistence and have major implications for the 
monitoring of CH-B and antiviral therapy. 
 
Materials and Methods  
Patients 
Biopsies were collected from a total of 98 CH-B patients corresponding to the relevant phases 
of the natural history including 63 patients with HBeAg+ active CH-B, 18 patients with 
HBeAg- CH-B (presumed precore mutant), 10 inactive carriers (HBsAg+, HBeAg-, 
antiHBeAb+), and 7 HBsAg seroconverters (serologically resolved patients with HBsAg-, 
anti HBsAb+, HBeAg-, antiHBeAb+). Thirty-two patients were also part of a phase III 
clinical trial evaluating the antiviral efficacy of ADV (10 patients received placebo, 22 
received 10 mg or 30 mg of ADV daily)
16
; baseline biopsies were included in the natural 
history study. Biopsies were stored at –80 C until experimental analysis.  
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Development and validation of quantitative cccDNA and total HBV DNA PCR assays 
Selective primers for cccDNA amplification (targeted across the single-stranded (SS) gap 
region of relaxed circular (RC) HBV DNA) and non-selective primers for total HBV DNA 
amplification (targeted to a double-stranded region of HBV DNA) were designed using 
oligo5 software (MedProbe, Olso, Norway) (Figure 1A.). To enhance the specificity of 
cccDNA detection, Plasmid-safe DNase (Epicentre, Madison, WI) was used to degrade RC 
and SS forms of viral DNA prior to PCR.  Selective and non-selective primers were able to 
efficiently amplify HBV contained in a closed circular plasmid regardless of DNase treatment 
(Fig. 1B). RC virion-associated HBV DNA extracted from the serum of a viremic patient 
could be amplified by both primer sets, however cccDNA primers were approximately 100-
fold less efficient (Fig. 1C). Plasmid-safe DNase treatment of virion-associated DNA 
prevented amplification, confirming that this DNase degraded RC forms of HBV DNA. 
Selective and non-selective primers were able to amplify HBV DNA extracted from a liver 
biopsy of a CH-B patient, regardless of Plasmid-safe DNase treatment (Fig 1D). The use of 
Plasmid-safe DNase was also validated by Southern blot analysis of intrahepatic WHV DNA 
(Fig 1E). Replicative intermediates and cccDNA were extracted from frozen woodchuck liver 
samples as described in detail
7
. After cell lysis, samples were divided in two, one for 
cccDNA extraction and one for total DNA purification. Briefly, cccDNA was isolated from 
the supernatant after precipitation of protein-DNA-detergent-complexes by 0.25 volumes of 
2.5M KCL. The supernatant was extracted twice with phenol, phenol-chloroform prior to 
ethanol precipitation. Total DNA was digested with Proteinase K prior to phenol extraction 
and ethanol precipitation. Twenty g of total viral DNA were digested using the Plasmid-safe 
DNase. Twenty g of DNA corresponding to : i) total viral DNA, ii) total viral DNA digested 
with the plasmid-safe DNase, iii) cccDNA preparation, were subjected to agarose gel 
electrophoresis and Southern blotting. As shown on the autoradiogram, the DNase efficiently 
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degraded replicative DNA intermediates but not cccDNA. The pattern of migration of viral 
DNA was similar in the total DNA digested with the Plasmid-safe DNase and in the cccDNA 
preparation. Note that the cccDNA preparation specifically enriches the extract for low 
molecular weight DNA and does not represent the same amount of starting cells as in the 
total DNA lanes.  
Quantification of cccDNA and total intracellular HBV DNA in patient biopsies 
DNA was extracted from biopsies using the MasterPure DNA purification kit (Epicentre). 
Before cccDNA amplification, aliquots of each DNA were treated with plasmid-safe DNase. 
Real-time PCR was performed in a LightCycler (Roche, Grenoble, France) using a 20 µl 
reaction volume containing 20ng of DNA (for cccDNA quantification, a volume equivalent 
to 20ng prior to DNase treatment), 3 mM MgCl2, 0.5 µM of forward and reverse primers, 0.2 
µM of 3’-fluorescein (FL) labeled  probe, and 0.4 µM of 5’-Red640 (R640) labeled probe.  
Forward and reverse primers were 5’-CTCCCCGTCTGTGCCTTCT-3’ (NCCC1 nt 1548-
1566) and 5’-GCCCCAAAGCCACCCAAG-3’ (CCCAS2 nt 1903-1886) for cccDNA 
amplification, respectively and 5’-CTCGTGGTGGACTTCTCTC-3’ (2RC/CCS nt 256-274) 
and 5’-CTGCAGGATGAAGAGGAA-3’ (2RC/CCAS nt 421-404) for total intrahepatic 
HBV DNA amplification, respectively. FRET hybridization probes were 5’-
GTTCACGGTGGTCTCCATGCAACGT-FL-3’and5’-R640-AGGTGAAGCGAAGTGCACA 
CGGACC-p-3’ for cccDNA quantification and 5’CACTCACCAACCTCCTGTCCTCCAA -
FL-3’ and 5’- R640-TGTCCTGGTTATCGCTGGATGTGTCT-3’ for total intrahepatic HBV 
DNA quantification. Amplification of total HBV DNA was performed as follows: 95°C for 
10 minutes, then 45 cycles of 95°C for 10 seconds, 58°C for 10 seconds, and 72°C for 15 
seconds. Amplification of cccDNA was performed as follows: 95°C for 10 minutes, then 45 
cycles of 95°C for 10 seconds, 58°C for 5 seconds, 10 seconds at 63°C, 72°C for 20 seconds. 
-globin amplification was performed using the LightCycler -globin control kit (Roche). 
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Serial dilutions of a plasmid containing an HBV monomer (pHBVEcoRI) served as 
quantification standards. Liver biopsies from uninfected patients were analyzed as negative 
controls. The detection limits were 3 x 10
-4
 and 2 x 10
-4
 copies/cell for the cccDNA and of 
total HBV DNA assays, respectively. Patient samples were independently analyzed in 
duplicate at three different sites (Lyon, France; Melbourne, Australia; Hamburg, Germany). 
Eighty two of 130 samples were analyzed at three sites and 129/130 samples were analyzed 
at two sites. Despite some variability, there was a significant correlation in the cccDNA and 
total intracellular DNA results obtained at each site (P0.001, for all pairwise comparisons). 
Results from the three sites were integrated by averaging cccDNA and total intracellular 
HBV DNA values (in log10 copies/cell) for each patient. Biopsies from the ADV study were 
analyzed while blinded to treatment assignment. To ensure cccDNA amplification signals 
were not due to HBV DNA integrated into host cell genomes, an HBV-Alu-specific PCR 
assay was performed on 13 extracted liver biopsy specimens as previously described 
18
.  
Immunostaining of liver samples for HBV core antigen 
Immunostaining for HBsAg and HBcAg was performed using a Dako Auto-Stainer and the 
Dako Envison+ system with peroxidase and 3,3’-diaminobenzidine chromogen (Dako, 
Carpenteria, CA). Primary antibodies were rabbit polyclonal antibody to HBcAg (Dako), 
used at a 1:600 dilution and monoclonal antibody to HBsAg (Zymed, San Francisco, CA), 
used at a 1:2000 dilution. The percentage of cells containing the chromogen, if present, was 
estimated in the ranges of 0%,  5%, 5-25%, 26-50%, 51-75%, and 75%. 
Detection of HBsAg titers in serum samples 
HBsAg titers in patient sera were quantified using an ELISA assay (Monolisa AgHBs plus, 
Biorad France) with purified HBsAg as standard (Hytest, Finland).  
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Statistical analysis  
Statistical comparisons were performed using SAS v8.1 (SAS Institute Cary, NC USA). 
Two-group comparisons were performed using Wilcoxon rank-sum tests; comparisons of 
more than 2 groups were made using Kruskal-Wallis tests. All pair-wise comparisons were 
made by Pearson correlation. Analyses of the predictive value of baseline parameters on 
changes in cccDNA were made by linear regression after modeling cccDNA changes as a 
function of treatment (ADV vs. placebo) and the potential predictive factor. P values <0.05 
were considered significant. 
 
Results 
cccDNA levels during different phase of the natural history of chronic hepatitis B. 
We developed and validated a real-time PCR assay for the specific detection of cccDNA and 
total intracellular HBV DNA in liver biopsies. Using this assay, a panel of 98 patients in 
different phases of the natural history of CH-B 
1,2
 were analyzed. cccDNA and total 
intracellular HBV DNA were measured and normalized to per cell values (using the cellular 
-globin gene) at three independent laboratories and the results were integrated. Median 
intrahepatic cccDNA levels in patients with hepatitis B e antigen positive (HBeAg+) CH-B 
(1.4 copies/cell) were significantly higher than in HBeAg- patients (0.01 copies/cell; 
P<0.001), or inactive carriers (0.02  copies/cell; P<0.001) (Fig. 2A). Patients with evidence 
of hepatitis B surface antigen (HBsAg) clearance had extremely low levels of cccDNA (0.002 
copies/cell; P<0.001, compared to HBeAg+ patients). Similarly, median total intracellular 
HBV DNA levels in HBeAg+ patients (155 copies/cell) were significantly higher compared 
to HBeAg- patients (0.6 copies/cell; P<0.001), inactive carriers (2 copies/cell) (P<0.001), and 
HBsAg- patients (0.19 copies/cell; P<0.001) (Fig 2B). Levels of cccDNA and total 
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intracellular HBV DNA were both highly correlated with viral load (HBV DNA) in serum of 
these patients (P<0.001, data not shown). 
Effect of 48 weeks of adefovir dipivoxil therapy on cccDNA levels in patients.  
We next determined the effect of 48 weeks of ADV therapy on cccDNA and total 
intrahepatic HBV DNA in 32 patients (22 treated, 10 placebo) with HBeAg+ CH-B. Our 
integrated analysis revealed median changes in cccDNA and total intrahepatic HBV DNA in 
ADV-treated patients of -0.80 and -1.63 log10 copies/cell, respectively (Fig 3 A and B). This 
equates to an 84% reduction of cccDNA and 98% reduction of total intracellular HBV DNA 
by the end of treatment. Reductions in cccDNA and total intrahepatic HBV DNA were highly 
significant compared to placebo patients who had median changes of +0.32 and -0.0001 log10 
copies/cell in cccDNA and total intrahepatic HBV DNA, respectively (P=0.002, cccDNA, 
treated vs. placebo; P<0.001 total intracellular HBV DNA, treated vs. placebo). To ensure 
that the integrated results were not biased by the results from a single laboratory, we analyzed 
each site’s data independently (Fig. 3 D and E). Although absolute values for cccDNA and 
total intracellular HBV DNA varied between sites, the magnitudes of DNA loss were very 
similar and supported the integrated findings. Median changes in serum HBV DNA were –
4.7 vs. –0.6 log10 copies/mL in ADV-treated and placebo patients, respectively (P<0.001) 
(Fig. 3C). Therefore, the decay rate of HBV replicative forms during ADV therapy can be 
ranked as follows: serum HBV DNA > total intracellular HBV DNA > cccDNA (Fig 3F).  
We also measured changes in HBsAg titers in the serum of ADV treated patients. At 
baseline, patients in the ADV and placebo groups had similar HBsAg titers (medians of 
332,599 and 217,378 ng/mL, respectively, p=0.48). After 48 weeks, patients receiving 
placebo had a median -0.09 log10 change in HBsAg titer (p=0.85 vs. baseline). However, 
patients receiving ADV therapy demonstrated a median 73% reduction in serum HBsAg 
(median change of -0.58 log10 ng/mL); this change was significant compared to baseline 
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(p<0.001) and compared to changes in placebo (p<0.001). Changes in HBsAg were 
significantly and positively correlated with changes in intrahepatic cccDNA (p=0.008), total 
intracellular HBV DNA (p=0.002), and serum HBV DNA (p<0.001). 
Interestingly, patients who underwent HBeAg seroconversion had significantly lower 
baseline levels of intracellular cccDNA compared to patients that remained HBeAg+ 
(p=0.034). However, patients receiving ADV underwent similar declines in cccDNA, 
regardless of whether they underwent HBeAg seroconversion (n=5, -0.94 log10 copies/cell) or 
not (n=17, -0.75 log10 copies/cell) (p=0.91). 
Immunohistochemical staining of biopsies for HBV antigens 
For patients in the ADV study, immunohistochemical staining was performed to determine 
the number of hepatitis B core antigen (HBcAg) and HBsAg positive cells in each biopsy 
(data not shown). In most biopsies, only a minority of the cells stained positive for HBcAg or 
HBsAg and positive cells tended to cluster together. There was a significant correlation 
between cccDNA copy number and the number of HBcAg+ cells (P=0.015, data not shown).  
A stronger correlation existed between the level of total intrahepatic HBV DNA and number 
of HBcAg+ cells (P<0.001, data not shown).  Normalization of cccDNA levels to the number 
of infected cells using HBcAg as a marker (instead of total cell number using -globin) 
yielded a median copy number of 33 copies per infected cell which is consistent with copy 
numbers derived from animal hepadnavirus models
7,8
. Although 48 weeks of antiviral therapy 
significantly decreased cccDNA levels, the number of infected (positive-staining) cells did 
not change significantly (data not shown), indicating a decrease in cccDNA copy number per 
cell rather than a loss of a proportion of infected cells.  
Correlation of cccDNA changes with baseline and post-therapy parameters 
Using the cccDNA and clinical data available for patients in the ADV study, we examined 
whether baseline parameters were predictive of cccDNA loss, and if changes in cccDNA 
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during therapy correlated with changes in other clinical parameters. Baseline ALT, liver 
histology (histological activity index), and viral load, using linear regression models were not 
predictive for cccDNA loss (Table 1). Changes in cccDNA were highly correlated with 
changes in total intrahepatic HBV DNA (P<0.001) as well as with changes in serum HBV 
DNA (P=0.008). We also examined if changes in cccDNA correlated with changes in ALT 
levels, liver histology, or the number of cells staining positive for either HBcAg, or HBsAg; 
none of these correlations were significant. 
 
 Discussion 
In this report, we describe the development of a novel and selective real-time PCR assay for 
quantifying cccDNA and total HBV DNA in liver biopsies from CH-B patients. This 
technique allowed, for the first time, an analysis of cccDNA levels in significant numbers of 
patients in different phases of the natural history of CH-B as well as a longitudinal analysis of 
patients undergoing antiviral therapy during a placebo-controlled study. This is noteworthy as 
these findings are likely derived from the last placebo-controlled trial in CH-B patients
19
. 
Our cross-sectional natural history study revealed that cccDNA levels were significantly 
higher in HBeAg+ patients compared to HBeAg- patients, inactive carriers, and patients who 
underwent HBsAg clearance. This result is consistent with our observations of greater levels 
of intrahepatic HBV replicative intermediates and serum HBV DNA in HBeAg+ patients 
(compared to the later groups) and with previous reports of viral load in HBeAg+ and 
HBeAg- patients
20
. Surprisingly, cccDNA levels in HBeAg- patients, who are infected with 
precore mutant HBV and have active liver disease, were not significantly different (P=0.68), 
than those in inactive carriers who have no evidence of ongoing liver disease. This is 
potentially attributable to the natural variation in HBV replication levels observed in patients 
infected with pre-core mutant HBV
21
, and the relatively small sample size for the inactive 
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carrier group (Figure 2A and 2B). However, these data could also indicate that the primary 
difference between a patient with HBeAg- active hepatitis and an inactive carrier is due to 
immunological rather than virological factors 
2,22
. 
The observation that cccDNA remained detectable in all HBeAg- patients explains why viral 
reactivation has been observed, to varying frequencies, in all these patient groups.  Indeed, 
fluctuating levels of viral replication and hepatitis are common in patients with precore 
mutant infection
22
. Viral reactivation and hepatitis flares have also been observed, albeit less 
frequently, in inactive carriers during long-term natural history studies
23-25
. Even patients 
with serological evidence of HBV clearance can develop active disease during periods of 
severe immune suppression such as transplantation, cancer chemotherapy, or steroid use
26,27
. 
The observed low-level persistence of cccDNA also explains the occurrence of de novo HBV 
infection in liver transplant patients who received grafts from donors that previously resolved 
infection
28
. Overall, our observations from the natural history study are consistent with the 
theory that resolution of hepadnaviral infection does not occur through “sterilizing immunity” 
but rather by consistent control of viral replication by the host immune system
29
.  
Clinical trials of nucleoside analogs have indicated that short-term therapy is followed 
by viral recrudescence in most CH-B patients
30,31
. Studies performed in animal hepadnavirus 
models suggested that the long half-life of viral cccDNA is responsible for viral persistence 
and reactivation following drug cessation
6,32,33
. Here we show, for the first time, that antiviral 
therapy with a potent HBV polymerase inhibitor significantly reduces cccDNA in CH-B 
patients. Importantly, reductions in cccDNA were correlated with, and similar in magnitude 
to, reductions in serum HBsAg titer. The parallel change in HBsAg provides further evidence 
that transcriptionally-active cccDNA is being depleted during therapy.  
The rate of cccDNA loss was nearly an order of magnitude lower than that of intracellular 
HBV replicative intermediates and several orders of magnitude lower than the rate of serum 
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HBV DNA loss (Figure 3).  Factors contributing to the relatively slow loss of cccDNA during 
therapy potentially include 1) the existence of cccDNA as a chromatinized episome
4 
2) the 
asymmetric nature of hepadnaviral replication which protects cccDNA from being directly 
depleted by chain-terminating polymerase inhibitors
3,6,14
, 3) the preferential use of mature 
viral nucleocapsids to replenish cccDNA pools during periods of reduced replication
5,6
 and 4) 
the potential for hepatocyte re-infection by residual circulating virus
34
.  
Results from our study potentially explain those of kinetic analyses of viral load decay during 
potent antiviral therapy.  Two main phases of viral load decline have previously been 
identified: a first phase of rapid viral decline (attributed to the inhibition of viral production 
in infected cells) and a second phase of slow decline (hypothesized to represent the clearance 
of infected cells)
35
. The slow rate of cccDNA clearance that we observed is likely to 
contribute to the slower second phase kinetic. The observed longevity of cccDNA also 
reinforces the prediction that long-term antiviral therapy will be required to control HBV 
replication unless a vigorous host immune response is mounted
36
. In this respect, our results 
are reminiscent of studies of HIV proviral DNA
37,38
. Fortunately, treatment of CH-B patients 
with potent nucleos/tides such as lamivudine and adefovir dipivoxil can result in partial 
restoration of immune responses which are necessary for the durable host-mediated control of 
infection
39,40
 (Cooksley et al., submitted).  
Mechanisms for clearance of viral cccDNA are being actively debated. Based on results of 
acute hepadnaviral infections in chimpanzees and woodchucks, it is unclear whether the 
primary clearance mechanism of hepadnavirus infection is mediated by a non-cytolytic TH-1 
immune response
10,41
 or by immune-mediated cell killing, followed by hepatocyte cell 
division
9,42,43,44
. While both mechanisms are likely to factor into viral clearance, our data 
support the former mechanism. Immunohistochemical staining did not identify a significant 
correlation between loss of cccDNA and the disappearance of viral antigen expressing cells, 
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suggesting that cccDNA loss during antiviral therapy occurred at a similar rate in most cells, 
rather than by the clearance or destruction of a subset of infected cells.  We hypothesize that 
decreases in intrahepatic cccDNA were primarily due to the potent suppression of viral DNA 
synthesis which would effectively deplete the pool of mature cytoplasmic nucleocapsids 
available for conversion into cccDNA
33,34
. Our analyses also indicated that cccDNA 
clearance during antiviral therapy was not significantly correlated with baseline indicators of 
host-mediated hepatocyte lysis (e.g. high baseline ALT levels and high baseline histological 
activity index). This also suggests that the clearance of cccDNA during antiviral therapy may 
be occurring primarily through a mechanism other than infected cell killing. Based on a 
mathematical modeling using cccDNA data derived from patients in the ADV sub-study, it 
would take approximately 14.5 years to completely clear a chronically HBV infected human 
liver of intracellular cccDNA
45
. However, since intracellular cccDNA remained detectable in 
patients that resolved chronic hepatitis B (HBsAg seroconverters, Figure 2A), it may not be 
necessary to completely eradicate cccDNA to establish long-term control of HBV infection.  
Despite the widespread availability of quantitative PCR technology, it is not currently 
practical to measure cccDNA in biopsies during routine clinical practice. However, 
monitoring cccDNA may provide an endpoint if a threshold can be determined, below which 
host-mediated control is likely to establish control of viral replication. Further longitudinal 
studies are ongoing to investigate such endpoints. 
In conclusion, our study of HBV cccDNA in the livers of chronically-infected patients 
provides new insight on the persistence of cccDNA throughout the natural history of CH-B, 
and on the kinetics of cccDNA clearance during potent antiviral therapy. Our observations, 
together with previously published clinical studies 
16, 17, 30, 31, 35, 36
 further support the 
argument for long-term antiviral therapy using agents that are both potent and have a low 
incidence of viral resistance. In this regard, additional clinical studies focusing on virological 
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outcomes are ongoing. The development of rational combination regimens may enhance 
antiviral response and further minimize resistance, thus fostering the progressive clearance of 
cccDNA reservoirs and enhanced anti-HBV immune responses.  
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Figure Legends 
Figure 1. Design and validation of a selective assay for HBV cccDNA amplification. A, PCR 
primers for amplification of cccDNA are targeted to opposite sides of the single-stranded gap 
regions of relaxed circular (RC) HBV DNA. B, Both non-selective primers and selective 
cccDNA primers are able to efficiently amplify a circular HBV encoding plasmid in the 
absence or presence of Plasmid-safe DNase. C, Relaxed circular HBV DNA derived from 
patient sera can be detected using either non-selective or selective cccDNA primers; however 
amplification with the cccDNA specific primers is approximately 100-fold less efficient.  
After digestion with Plasmid-safe DNase, virion-derived RC DNA was not detected with 
either primer pair. D, Amplification of extracted liver DNA using either non-selective or 
selective cccDNA primers allows the detection of nuclease-resistant cccDNA. E, Southern 
blot analysis were performed using woodchuck liver samples, after extraction of replicative 
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intermediates and cccDNA according to two DNA extraction procedures (see Material and 
Methods section).  
Figure 2.  cccDNA and total intracellular HBV DNA levels in patients belonging to distinct 
natural history groups. A, cccDNA levels in patients with chronic active HBeAg+ hepatitis B 
(HBeAg+), chronic active HBeAg- hepatitis B (HBeAg-), inactive carriers patients (Inactive) 
and patients that have cleared HBV infection (HBsAg-). Each point represent a single patient 
with the bars indicating median values. LLOD: lower limit of detection. B. Total intracellular 
HBV DNA levels in the same groups of patients.  
Figure 3. Effect of 48 weeks of adefovir dipivoxil therapy on cccDNA, total intracellular 
HBV DNA and serum HBV DNA levels. A,  Change in cccDNA levels between baseline and 
week 48 in 22 ADV-treated patients and 10 placebo (PBO) patients, integrated results. Each 
point represents the baseline to week 48 change of a single patient with the bars indicating 
median values. B, Change in total intracellular HBV DNA levels between baseline and week 
48 in 22 ADV-treated patients and 10 PBO patients, integrated results. C, Change in serum 
HBV DNA levels between baseline and week 48 in ADV-treated and PBO patients. D, 
Change in cccDNA levels between baseline and week 48 in ADV-treated and placebo 
patients as reported by individual analysis sites (Lyon, Hamburg, Melbourne), bars represent 
median values and error bars indicate interquartile ranges. E, Change in total intracellular 
HBV DNA levels between baseline and week 48 in ADV-treated and PBO patients as 
reported by individual analysis sites. F, Comparison of rates of serum HBV DNA, total 
intracellular HBV DNA and cccDNA loss in ADV-treated and PBO patients.  
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Table 1: Correlation of changes in cccDNA copy number with baseline and post-treatment 
parameters. 
 
Correlation P Value 
Baseline viral load 0.15 
Baseline HAI 0.97 
Baseline ALT 0.86 
Change in Serum HBV DNA  0.008 
Change in Total Intracellular HBV DNA <0.001    
Change in ALT  0.76 
Change in HAI 0.709 
Change in number of cells positive for 
nuclear HBcAg 
0.48 
Change in number of cells positive for 
cytoplasmic HBcAg 
0.70 
Change in number of HBsAg-positive cells  0.59 
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